Table 2.
Potential prognostic factor for disease-free survival and overall survival
|
|
Disease free survival (DFS)
|
P
value
|
Overall survival (OS)
|
P
value
|
||||
|
3 yr (%)
|
5 yr (%)
|
10 y (%)
|
3 yr (%)
|
5 yr (%)
|
10 yr (%)
|
|||
| CEA | 0.095 | 0.045 | ||||||
| < 5 ng/mL | 84.4 | 80.8 | 73.1 | 88.3 | 79.8 | 69.6 | ||
| ≥ 5 ng/mL | 72.2 | 61.1 | 50.0 | 81.0 | 66.7 | 42.9 | ||
| AJCC stage | < 0.0001 | < 0.0001 | ||||||
| 1 | 86.9 | 82.9 | 70.6 | 91.1 | 83.5 | 70.4 | ||
| 2 | 87.7 | 76.2 | 57.9 | 92.9 | 82.1 | 54.3 | ||
| 3 | 59.3 | 57.9 | 50.6 | 72.0 | 61.0 | 48.5 | ||
| 4 | 20.0 | - | - | 63.6 | 45.5 | 18.2 | ||
| Pathologic M stage1 | < 0.0001 | 0.002 | ||||||
| 0 | 77.0 | 71.2 | 58.4 | 85.1 | 74.4 | 57.0 | ||
| 1 | 20.0 | - | - | 63.6 | 45.5 | 18.2 | ||
| Retrieved LN | 0.819 | 0.688 | ||||||
| < 12 | 81.5 | 75.4 | 58.1 | 87.5 | 76.4 | 54.7 | ||
| ≥ 12 | 73.3 | 69.3 | 58.8 | 83.2 | 73.8 | 56.4 | ||
| LN ratio | 0.068 | 0.043 | ||||||
| < 15 | 66.8 | 64.0 | 55.6 | 78.0 | 70.7 | 56.0 | ||
| ≥ 15 | 41.5 | 41.5 | 36.2 | 61.7 | 44.7 | 33.8 | ||
| Timing of recurrence | 0.028 | |||||||
| Early (< 3 yr2) | 54.9 | 33.3 | 11.8 | |||||
| Late (≥ 3 yr2) | 100 | 77.8 | 22.2 | |||||
1
According to the tumor node metastasis staging system.
2
Recurrence from the first treatment.
CEA: Carcinoembryonic antigen; AJCC: American Joint Committee on Cancer; LN: Lymph node.